歐亞集團(600697.SH):擬向銀行申請綜合授信額度共計20.5億元
格隆匯 7 月 1日丨歐亞集團(600697.SH)公佈,根據公司經營發展需要,董事會同意向下列銀行申請綜合授信額度共計20.5億元人民幣。
1、向吉林銀行股份有限公司長春衞星支行申請新增授信額度4.5億元人民幣,授信品種為流動資金貸款,期限為一年,擔保方式為信用。
2、向興業銀行股份有限公司長春分行申請授信總額12億元人民幣,授信品種為流動資金貸款、銀行承兑匯票、匯票貼現,用於經營週轉及置換他行貸款,期限為一年。
3、向招商銀行股份有限公司長春分行申請授信總額4億元人民幣,授信品種為流動資金貸款、銀行承兑匯票、國內買方保理、自助貸款、商票保貼,用於日常經營週轉,期限為一年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.